GlassScriptPhysician profile
Bethany A Graham
NPI 1225345549
$3,946.64
in general payments reported to CMS, 2019-2025
38 companies · $863 in 2025
The $863 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $632 · 2022: $890 · 2023: $802 · 2024: $759 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $706.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $375.31 | 2021-2025 | |
| Abbvie INC. | $312.05 | 2022-2025 | |
| Lilly USA, LLC | $279.00 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $244.14 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $238.23 | 2021-2025 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $215.98 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.42 | 2021-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $151.39 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $137.35 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $101.15 | 2021-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $101.14 | 2021 | |
| Abbott Laboratories | $79.34 | 2023-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $76.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.94 | 2021-2025 | Xifaxan |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.